Search for: "State of IN v. Amgen, Inc., et al"
Results 21 - 40
of 75
Sorted by Relevance
|
Sort by Date
4 Mar 2016, 12:25 pm
Daiichi Sankyo, Inc., et al. v. [read post]
12 Oct 2011, 11:56 am
Amgen, Inc. et al., No. 1:06-cv-10972-WGY, (D. [read post]
28 Sep 2016, 8:39 am
Amgen Inc., et al., No. 16-332 (effectively extending exclusivity to 12 1/2 years; complement to the Sandoz petition) Mylan Pharmaceuticals, et al. v. [read post]
31 Dec 2023, 4:29 pm
Goldsmith et al. [read post]
8 Feb 2017, 3:09 am
(Appeal from MD State Court) Anticipation/Obviousness: Google Inc., et al. v. [read post]
13 Oct 2016, 6:50 am
Amgen Inc., et al., No. 16-332 (effectively extending exclusivity to 12 1/2 years; complement to the Sandoz petition) Eligibility: Trading Technologies International, Inc. v. [read post]
16 Jan 2017, 5:44 pm
(Appeal from MD State Court) Anticipation/Obviousness: Google Inc., et al. v. [read post]
14 Nov 2016, 9:16 am
Amgen Inc., et al., No. 16-332 (effectively extending exclusivity to 12 1/2 years; complement to the Sandoz petition) Licensing: DataTreasury Corp. v. [read post]
7 Sep 2010, 6:10 pm
Genpharm Inc. et al. [read post]
3 Jun 2016, 6:40 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
18 Apr 2016, 9:58 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
26 Dec 2011, 7:57 pm
State of New York et al. and Blackstone Medical Inc., v. [read post]
27 Aug 2012, 11:01 am
Relying on our decision in Amgen Inc. v. [read post]
3 May 2016, 1:42 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
18 May 2016, 8:19 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
1 Apr 2016, 8:22 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
17 Mar 2016, 2:45 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
28 Jun 2016, 6:41 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
24 Feb 2022, 6:12 pm
Daktronics, Inc., et al., No. 21-438 (CVSG requested October 4, 2021); and Appellate Standing for IPR Challenger: Apple Inc. v. [read post]
14 Dec 2021, 9:57 am
There are two other eligibility cases pending: Yanbin Yu, et al. v. [read post]
